NCT04270175View on ClinicalTrials.gov

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 14, 2021

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2027

Conditions
AmyloidAL AmyloidosisRefractory AL Amyloidosis
Interventions
DRUG

Daratumumab SC

Given as 1800mg via injection

DRUG

Pomalidomide

Given as 4mg oral capsule

DRUG

Dexamethasone

Given as 20mg or 40 mg IV and 20mg or 40mg oral tablet.

Trial Locations (4)

10065

Weill Cornell Medicine - Multiple Myeloma Center, New York

53226

Medical College of Wisconsin, Milwaukee

94304

Stanford University, Palo Alto

02118

Boston University Medical Center, Boston

All Listed Sponsors
collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER